International Journal of Scientific Research in Dental and Medical Sciences

International Journal of Scientific Research in Dental and Medical Sciences

The Effect of Treatment with Mesenchymal Stem Cells on HbA1c and Insulin Requirement in Diabetic Patients: A Systematic Review and Meta-analysis

Document Type : Review Article

Authors
Parsa Eshragh Abad Shapori 1
Maryam Fathi 2
1 Faculty of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran
2 Faculty of Health Sciences of Sorbonne, Antoine Béclère hospital, Paris, France
10.30485/ijsrdms.2025.532144.1664
Abstract
Background and aim: This study explores the use of mesenchymal stem cells (MSCs) as a potential therapeutic option for diabetes treatment, addressing the increasing global prevalence of the condition, the lack of glucose control, the need for insulin injections, patient quality of life, and associated side effects. It investigates the impact of MSC treatment on HbA1c levels and insulin requirements in patients with diabetes.
Material and methods: The present study included 13 RCT studies from international databases (PubMed, EMBASE, Web of Science, and Cochrane Library) up to April 30, 2025, identified using relevant keywords and based on study inclusion and exclusion criteria. The statistical analysis was performed using Stata/MP v17 as a fixed-effects model.
Results: HbA1c levels in the group receiving MSC therapy were significantly lower than in the placebo group, with the mean changes of HbA1c being -0.72 (MD: -0.72; 95% CI, -0.95,-0.50). The mean changes of FPG in T1DM were -29.65 (MD: -29.65; 95% CI, -47.2, -12.28), and in T2DM were -0.68 (MD: -0.68; 95% CI, -1.56, -0.20). The test of group differences showed that the effectiveness of MSC therapy on both types of diabetes (T1DM and T2DM) in terms of C-peptide levels is similar (p = 0.08).
Conclusions: A decrease in HbA1c levels, a decrease in fasting blood sugar, and an increase in C-peptide levels were observed after treatment with mesenchymal stem cells compared to the placebo group, indicating that mesenchymal stem cells can effectively affect the treatment process of diabetes.
Keywords
Diabetes Mellitus
Insulin
Mesenchymal Stem Cells

Subjects

[1] Yang X, Sun J, Zhang W. Global trends in burden of type 2 diabetes attributable to physical inactivity across 204 countries and territories, 1990-2019. Frontiers in Endocrinology. 2024;15:1343002. https://doi.org/10.3389/fendo.2024.1343002.
[2] Tremblay J, Hamet P. Environmental and genetic contributions to diabetes. Metabolism. 2019;100:153952. https://doi.org/10.1016/j.metabol.2019.153952.
[3] Katsarou A, Gudbjörnsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, et al. Type 1 diabetes mellitus. Nature reviews Disease primers. 2017;3(1):1-7. https://doi.org/10.1038/nrdp.2017.16.
[4] Ruze R, Liu T, Zou X, Song J, Chen Y, Xu R, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Frontiers in endocrinology. 2023;14:1161521. https://doi.org/10.3389/fendo.2023.1161521.
[5] Gregory GA, Robinson TI, Linklater SE, Wang F, Colagiuri S, de Beaufort C, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. The lancet Diabetes & endocrinology. 2022;10(10):741-60. https://doi.org/10.1016/S2213-8587(22)00218-2.
[6] Gregg EW, Buckley J, Ali MK, Davies J, Flood D, Mehta R, et al. Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact. the lancet. 2023;401(10384):1302-12. https://doi.org/10.1016/S0140-6736(23)00001-6.
[7] Kropp M, Golubnitschaja O, Mazurakova A, Koklesova L, Sargheini N, Vo TT, et al. Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications—risks and mitigation. Epma Journal. 2023;14(1):21-42. https://doi.org/10.1007/s13167-023-00314-8.
[8] Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. Nature Reviews Endocrinology. 2022;18(9):525-39. https://doi.org/10.1038/s41574-022-00690-7.
[9] Capuzzo MA, Ossanna R, Quintero Sierra LA, Virla F, Negri A, Conti A, et al. From the classification of stem cells to the release of potential in cell therapies: limits, considerations and future aspects in regenerative medicine. InPossibilities and limitations in current translational stem cell research 2023;44:1-17.
[10] Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell transplantation. 2016;25(5):829-48. https://doi.org/10.3727/096368915X689622.
[11] Friedenstein AJ, Chailakhjan RK, Lalykina K. The development of fibroblast colonies in monolayer cultures of guinea‐pig bone marrow and spleen cells. Cell Proliferation. 1970;3(4):393-403. https://doi.org/10.1111/j.1365-2184.1970.tb00347.x.
[12] Li L, Li J, Guan H, Oishi H, Takahashi S, Zhang C. Human umbilical cord mesenchymal stem cells in diabetes mellitus and its complications: applications and research advances. International journal of medical sciences. 2023;20(11):1492-1507. https://doi.org/10.7150/ijms.87472.
[13] Al Naem M, Bourebaba L, Kucharczyk K, Röcken M, Marycz K. Therapeutic mesenchymal stromal stem cells: Isolation, characterization and role in equine regenerative medicine and metabolic disorders. Stem cell reviews and reports. 2020;16:301-22. https://doi.org/10.1007/s12015-019-09932-0.
[14] Ghassemifard L, Hasanlu M, Parsamanesh N, Atkin SL, Almahmeed W, Sahebkar A. Cell therapies and gene therapy for diabetes: current progress. Current Diabetes Reviews. 2025;21(8):e130524229899. https://doi.org/10.2174/0115733998292392240425122326.
[15] Tugwell P, Tovey D. PRISMA 2020. Journal of Clinical Epidemiology. 2021;134:A5-6. https://doi.org/10.1016/j.jclinepi.2021.04.008.
[16] Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: Advantages and limitations of the Newcastle Ottawa Scale. World Journal of Meta-Analysis. 2017;5(4):80-4. http://dx.doi.org/10.13105/wjma.v5.i4.80.
[17] Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Assessing risk of bias in a randomized trial. Cochrane handbook for systematic reviews of interventions. 2019:205-28. https://doi.org/10.1002/9781119536604.ch8.
[18] Carlsson PO, Espes D, Sisay S, Davies LC, Smith CE, Svahn MG. Correction: Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a Phase I/II randomised double-blind placebo-controlled trial. Diabetologia. 2025:1-2. https://doi.org/10.1007/s00125-023-05934-3.
[19] Wang Y, Chen H, Li Y, Hao H, Liu J, Chen Y, et al. Predictive factors that influence the clinical efficacy of umbilical cord–derived mesenchymal stromal cells in the treatment of type 2 diabetes mellitus. Cytotherapy. 2024;26(3):311-6. https://doi.org/10.1016/j.jcyt.2023.12.006.
[20] Zhu Y, Huang C, Zheng L, Li Q, Ge J, Geng S, et al. Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study. Stem Cell Research & Therapy. 2024;15(1):122. https://doi.org/10.1186/s13287-024-03707-2.
[21] Carlsson PO, Espes D, Sisay S, Davies LC, Smith CE, Svahn MG. Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a Phase I/II randomised double-blind placebo-controlled trial. Diabetologia. 2023;66(8):1431-41. https://doi.org/10.1007/s00125-023-05934-3.
[22] Lian XF, Lu DH, Liu HL, Liu YJ, Han XQ, Yang Y, et al. Effectiveness and safety of human umbilical cord-mesenchymal stem cells for treating type 2 diabetes mellitus. World Journal of Diabetes. 2022;13(10):877-87. https://doi.org/10.4239/wjd.v13.i10.877.
[23] Zang L, Li Y, Hao H, Liu J, Cheng Y, Li B, et al. Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial. Stem Cell Research & Therapy. 2022;13(1):180. https://doi.org/10.1186/s13287-022-02848-6.
[24] Izadi M, Sadr Hashemi Nejad A, Moazenchi M, Masoumi S, Rabbani A, Kompani F, et al. Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: A phase I/II randomized placebo-controlled clinical trial. Stem Cell Research & Therapy. 2022;13(1):264. https://doi.org/10.1186/s13287-022-02941-w.
[25] Wu Z, Xu X, Cai J, Chen J, Huang L, Wu W, et al. Prevention of chronic diabetic complications in type 1 diabetes by co-transplantation of umbilical cord mesenchymal stromal cells and autologous bone marrow: a pilot randomized controlled open-label clinical study with 8-year follow-up. Cytotherapy. 2022;24(4):421-7. https://doi.org/10.1016/j.jcyt.2021.09.015.
[26] Lu J, Shen SM, Ling Q, Wang B, Li LR, Zhang W, et al. One repeated transplantation of allogeneic umbilical cord mesenchymal stromal cells in type 1 diabetes: an open parallel controlled clinical study. Stem cell research & therapy. 2021;12(1):340. https://doi.org/10.1186/s13287-021-02417-3.
[27] Bhansali S, Dutta P, Kumar V, Yadav MK, Jain A, Mudaliar S, et al. Efficacy of autologous bone marrow-derived mesenchymal stem cell and mononuclear cell transplantation in type 2 diabetes mellitus: a randomized, placebo-controlled comparative study. Stem cells and development. 2017;26(7):471-81. https://doi.org/10.1089/scd.2016.0275.
[28] Hu J, Wang Y, Gong H, Yu C, Guo C, Wang F, et al. Long term effect and safety of Wharton's jelly-derived mesenchymal stem cells on type 2 diabetes. Experimental and therapeutic medicine. 2016;12(3):1857-66. https://doi.org/10.3892/etm.2016.3544.
[29] Cai J, Wu Z, Xu X, Liao L, Chen J, Huang L, et al. Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: a pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion. Diabetes care. 2016;39(1):149-57. https://doi.org/10.2337/dc15-0171.
[30] Hu J, Yu X, Wang Z, Wang F, Wang L, Gao H, et al. Long term effects of the implantation of Wharton’s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocrine journal. 2013;60(3):347-57.
[31] Hamad FR, Rahat N, Shankar K, Tsouklidis N. Efficacy of stem cell application in diabetes mellitus: promising future therapy for diabetes and its complications. Cureus. 2021;13(2):e13563. https://doi.org/10.7759/cureus.13563.
[32] Mathur A, Taurin S, Alshammary S. The safety and efficacy of mesenchymal stem cells in the treatment of type 2 diabetes-A literature review. Diabetes, Metabolic Syndrome and Obesity. 2023;16:769-77.
[33] Pawitan JA, Yang Z, Wu YN, Lee EH. Towards standardized stem cell therapy in type 2 diabetes mellitus: a systematic review. Current Stem Cell Research & Therapy. 2018;13(6):476-88. https://doi.org/10.2174/1574888X13666180502143657.
[34] Ranjbaran H, Mohammadi Jobani B, Amirfakhrian E, Alizadeh‐Navaei R. Efficacy of mesenchymal stem cell therapy on glucose levels in type 2 diabetes mellitus: A systematic review and meta‐analysis. Journal of Diabetes Investigation. 2021;12(5):803-10. https://doi.org/10.1111/jdi.13404.
[35] Nada AH, Ibrahim IA, Oteri V, Shalabi L, Asar NK, Aqeilan SR, et al. Safety and efficacy of umbilical cord mesenchymal stem cells in the treatment of type 1 and type 2 diabetes mellitus: a systematic review and meta-analysis. Expert Review of Endocrinology & Metabolism. 2025;20(2). https://doi.org/10.1080/17446651.2025.2457474.
[36] Association AD. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44:S7-14. https://doi.org/10.2337/dc21-S001.
[37] Hill NR, Levy JC, Matthews DR. Expansion of the homeostasis model assessment of β-cell function and insulin resistance to enable clinical trial outcome modeling through the interactive adjustment of physiology and treatment effects: iHOMA2. Diabetes care. 2013;36(8):2324-30. https://doi.org/10.2337/dc12-0607.
[38] Madan R, Varghese RT. Assessing insulin sensitivity and resistance in humans. Endotext. 2024.
[39] Päth G, Perakakis N, Mantzoros CS, Seufert J. Stem cells in the treatment of diabetes mellitus—Focus on mesenchymal stem cells. Metabolism. 2019;90:1-5. https://doi.org/10.1016/j.metabol.2018.10.005.
International Journal of Scientific Research in Dental and Medical Sciences
Volume 7, Issue 2
Spring 2025
Pages 88-95

  • Receive Date 02 March 2025
  • Revise Date 09 May 2025
  • Accept Date 10 June 2025
  • Publish Date 12 June 2025